Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748.
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
Au-Yeung RKH, Arias Padilla L, Zimmermann M, et al. Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group. Br J Haematol. 2020; 190(5):753-763.
Quintanilla-Martinez L, Laurent C, Soma L, et al. Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop. Virchows Arch. 2023;483(3):281-298.
Quintanilla-Martinez L, Sander B, Chan JK, et al. Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. Virchows Arch. 2016;468(2):141-157.
Salaverria I, Martin-Guerrero I, Burkhardt B, et al. High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas. Genes Chromosomes Cancer. 2013;52(2):150-155.
Chen L, Al-Kzayer LF, Liu T, Kobayashi N, Nakazawa Y, Koike K. IFR4/ MUM1-positive lymphoma in Waldeyer ring with co-expression of CD5 and CD10. Pediatr Blood Cancer. 2017;64(2):311-314.
Chisholm KM, Mohlman J, Liew M, et al. IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children’s Oncology Group trials. Pediatr Blood Cancer. 2019; 66(8):e27770.
Czarny J, Andrzejewska M, Zajac-Spychala O, et al. Successful treatment of large B-cell lymphoma in a child with compound heterozygous mutation in the ATM gene. Int J Mol Sci. 2023;24(2): 1099.
Elhodaky M, Gunderman LM, Bachula M, et al. Relapse of large B-cell lymphoma with IRF4 rearrangement associated with SLAM-associated protein deficiency. Pediatr Blood Cancer. 2023;70(9):e30478.
Ramis-Zaldivar JE, Gonzalez-Farre B, Balague O, et al. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood. 2020;135(4):274-286.
Woessmann W, Quintanilla-Martinez L. Rare mature B-cell lymphomas in children and adolescents. Hematol Oncol. 2019;37(suppl 1):53-61.
Minard-Colin V, Auperin A, Pillon M, et al. Rituximab for high-risk, mature B-cell non-Hodgkin’s lymphoma in children. N Engl J Med. 2020;382(23):2207-2219.
Pillon M, Mussolin L, Carraro E, et al. Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol. Br J Haematol. 2016;175(3):467-475.
Rigaud C, Auperin A, Jourdain A, et al. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: a report from the French LMB study. Pediatr Blood Cancer. 2019;66(9):e27873.
Tsurusawa M, Mori T, Kikuchi A, et al. Improved treatment results of children with B-cell non-Hodgkin lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediatr Blood Cancer. 2014;61(7):1215-1221.
Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948-958.
Jourdain A, Auperin A, Minard-Colin V, et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. AaSociete Francaise des Cancers de l’Enfant study. Haematologica. 2015;100(6):810-817.
Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332-339.
Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International pediatric non-Hodgkin lymphoma staging system. J Clin Oncol. 2015; 33(18):2112-2118.
Frauenfeld L, Castrejon-de-Anta N, Ramis-Zaldivar JE, et al. Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. Blood Adv. 2022;6(7):2361-2372.
Jiang XN, Yu F, Xue T, et al. IRF4 rearrangement may predict favorable prognosis in children and young adults with primary head and neck large B-cell lymphoma. Cancer Med. 2023;12(9):10684-10693.
Streich S, Frauenfeld L, Otto F, et al. Prevalence of IRF4 rearrangement in large B-cell lymphomas of the Waldeyer’s ring in adults. Virchows Arch. 2023;482(3):551-560.
Attarbaschi A, Abla O, Arias Padilla L, et al. Rare non-Hodgkin lymphoma of childhood and adolescence: a consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. Pediatr Blood Cancer. 2020;67(8):e28416.
Attarbaschi A, Beishuizen A, Mann G, et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a "Watch and wait" strategy after complete resection. Ann Hematol. 2013;92(11):1537-1541.
Xavier AC, Suzuki R, Attarbaschi A. Diagnosis and management of rare paediatric Non-Hodgkin lymphoma. Best Pract Res Clin Haematol. 2023;36(1):101440.
Ronceray L, Abla O, Barzilai-Birenboim S, et al. Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection. Pediatr Blood Cancer. 2018;65(4).
